86P Aumolertinib as adjuvant therapy in postoperative EGFR-mutated non-small cell lung cancer

Abstract

Aumolertinib (HS-10296) is a novel, promising oral third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI), which has demonstrated efficacy in tumours harbouring sensitive EGFR mutations and T790M resistance mutation. Aumolertinib has also been shown to have efficacy in CNS metastasis. However, the efficacy and safety of aumolertinib as adjuvant therapy in postoperative patients remains unknown.